8 news items
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
RYTM
11 Jun 24
adverse reactions (incidence ≥20%) included skin hyperpigmentation, injection site reactions, nausea, headache, diarrhea, abdominal pain, vomiting
Rhythm Pharmaceuticals Presents Patient-reported Experiences with Hyperphagia in Hypothalamic Obesity at ENDO 2024
RYTM
3 Jun 24
adverse reactions (incidence ≥20%) included skin hyperpigmentation, injection site reactions, nausea, headache, diarrhea, abdominal pain, vomiting
Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conference
RYTM
3 Jun 24
with benzyl alcohol-preserved drugs. ADVERSE REACTIONS Most common adverse reactions (incidence ≥20%) included skin
Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for ▼IMCIVREE® (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome
RYTM
22 May 24
Most common adverse reactions (incidence ≥20%) included skin hyperpigmentation, injection site reactions, nausea, headache, diarrhea, abdominal
Rhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting
RYTM
6 May 24
. ADVERSE REACTIONS Most common adverse reactions (incidence ≥20%) included skin hyperpigmentation
bcw7bgyjiskvpjtvj3i2ucvxms1gkyagj1wikywjf5l
RYTM
29 Apr 24
. ADVERSE REACTIONS Most common adverse reactions (incidence ≥20%) included skin hyperpigmentation, injection site reactions, nausea
nompqe9abxr5wofhlo4qyum7skdg54n57ai 01oc8tsknsmqom
RYTM
24 Apr 24
with benzyl alcohol-preserved drugs. ADVERSE REACTIONS Most common adverse reactions (incidence ≥20
cubhk1wexnwqmgmnnh9ybjeaa49vkc7f jb6dc5to93n8
RYTM
16 Apr 24
. ADVERSE REACTIONS Most common adverse reactions (incidence ≥20%) included skin hyperpigmentation, injection site reactions, nausea
- Prev
- 1
- Next